# A Study of CS060380 Tablets in Patients With MASH and Obesity

> **NCT07466017** · PHASE2 · RECRUITING · sponsor: **Cascade Pharmaceuticals, Inc** · enrollment: 120 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Obesity

## Interventions

- **DRUG:** semaglutide
- **DRUG:** CS060380
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07466017
- **Lead sponsor:** Cascade Pharmaceuticals, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07466017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07466017, "A Study of CS060380 Tablets in Patients With MASH and Obesity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07466017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*